Specific delivery of kinase inhibitors in nonmalignant and malignant diseases

Author： van Beuge Marike Marjolijn   Poelstra Klaas   Prakash Jai  

Publisher： Informa Healthcare

ISSN： 1742-5247

Source： Expert Opinion on Drug Delivery, Vol.9, Iss.1, 2012-01, pp. : 59-70

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug delivery strategies for cathepsin inhibitors in joint diseases

By Wang Dong   Brömme Dieter  

Expert Opinion on Drug Delivery, Vol. 2, Iss. 6, 2005-11 ,pp. : 1015-1028

Informa Healthcare

Access to resources Recommend Favorite

Extended-release opioids for the management of chronic non-malignant pain

By Sloan Paul   Babul Najib  

Expert Opinion on Drug Delivery, Vol. 3, Iss. 4, 2006-07 ,pp. : 489-497

Informa Healthcare

Access to resources Recommend Favorite

Convection-enhanced delivery of targeted toxins for malignant glioma

By Hall Walter A   Sherr Gregory T  

Expert Opinion on Drug Delivery, Vol. 3, Iss. 3, 2006-05 ,pp. : 371-377

Informa Healthcare

Access to resources Recommend Favorite

Nanotechnology controlled drug delivery for treating bone diseases

By Yang Lei   Webster Thomas J  

Expert Opinion on Drug Delivery, Vol. 6, Iss. 8, 2009-08 ,pp. : 851-864

Informa Healthcare

Access to resources Recommend Favorite

Carbon nanotubes in drug delivery: focus on infectious diseases

By Rosen Yitzhak   Elman Noel M  

Expert Opinion on Drug Delivery, Vol. 6, Iss. 5, 2009-05 ,pp. : 517-530

Informa Healthcare

Access to resources Recommend Favorite